Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Algernon on Facebook to discuss Topline Data today at 12:00
View:
Post by Cookie2018 on Apr 05, 2021 10:49am

Algernon on Facebook to discuss Topline Data today at 12:00

The Facebook Live will be held today, Monday, April 5, 2021, hosted by Cyndi Edwards of PRMediaNow at 12:00 PM EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.

When: Monday, April 5, 2021 12:00 PM Eastern Time (US and Canada)

Topic: Topline Data for Phase 2b/3 COVID-19 Trials of Ifenprodil

Guests: Algernon Pharmaceuticals CEO, Christopher J. Moreau and VP, Dr. Christopher Bryan with host Cyndi Edwards

Be the first to comment on this post
Algernon Pharmaceuticals Inc.